Financial Results for Full Year 2007: NicOx Significantly Advances Clinica... (302 Minority interests in equity ...)

(Date:12/4/2009)... Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ) ... provide therapy equipment and rehab supplies to Benchmark Physical ... ,, "We are pleased to be named the ... Beardall, executive vice president of sales and marketing at ...

(Date:12/4/2009)... WASHINGTON, Dec. 4 Chemistry World recently highlighted ... Research and Manufacturers of America ( PhRMA ) that ... and related conditions. ,, The report found that ... antivirals. These drugs are either in human clinical trials or ...

(Date:12/4/2009)... Inc. (NYSE Amex: PIP ), a biodefense ... threats, announced today that the Company is presenting ... Valortim® in an inhalation anthrax model in the ... are being presented during an oral session at ...

Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2 PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2 PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3 PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4 PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5 PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6 Influenza monitoring by the US military 50914 1 Influenza monitoring by the US military 50914 2 Food crisis and global health workshop July 14 16 50910 1 When it comes to brain damage blankets take the place of drugs 9135 1

[0] Dynatronics Named Sole-Source Supplier to Benchmark Physical Therapy [0] U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS [0] PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop

... phase II/III study demonstrates C1-INH is effective treatment for ... ... 6 CSL Behring has submitted,a biologics license application (BLA) to ... C1-esterase,inhibitor concentrate in the United States for the treatment of hereditary,angioedema ...

... demonstrates BSGI is ... both patient and cost effective., NEWPORT NEWS, ... Bertrand, Director of Breast Imaging at Solis Bertrand Breast,Center in ... (BSGI) as an adjunctive procedure in breast,diagnostics; specifically demonstrating BSGI ...

Other Medicine Technology:CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema 2 Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics 2 Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics 3

CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics

(Date:12/7/2009)... Dec. 7 Today the Centers for Disease ... Influenza Vaccination Week. While the week was designed to ... to light the importance of taking additional steps to ... cold and flu season of December, January and beyond. ... information circulating around the topic of both seasonal and ...

(Date:12/7/2009)... may suffer from more emotional and behavioral difficulties when ... girls struggling the most when a parent is deployed ... Researchers found that having a parent deployed for a ... who has struggled with emotional problems were important factors ... to the study published online by the journal ...

(Date:12/7/2009)... be able to reverse some of the damage to ... down their cigarettes, according to research out of the ... research is published in the December 15 issue of ... and Critical Care Medicine . , "We found that ... of the epithelium, or lining, of the airways in ...

(Date:12/6/2009)... Dec. 6 Pharmacyclics, Inc. (Nasdaq: ... Phase I/II study showing safety and clinical activity ... (NHL) treated with its HDAC inhibitor PCI-24781 as ... at the 51st ASH Annual Meeting being held ... ,, PCI-24781 is an oral pan-HDAC inhibitor which ...

(Date:12/6/2009)... a mainstay of multiple myeloma treatment may outperform ... patients who have received stem cell transplants from ... trial results to be presented by , ... of Hematology,s (ASH) annual meeting on Sunday, Dec. ... Room 243-245, 5:45 pm CT). , The ...

Breaking Medicine News(10 mins):Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2 Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3 Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2 Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3 Health News:Quitting smoking can reverse asthma-inducing changes in lungs 2 Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2 Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3 Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4 Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5 Health News:Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients 2

[1] As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu [0] Military children face more emotional challenges as parental deployments grow longer, study finds [0] Quitting smoking can reverse asthma-inducing changes in lungs [1] Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting [0] Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients

... of Blacksburg, Va., a professor of virology in the ... Sciences and Pathobiology at Virginia Tech, has been awarded ... National Institutes of Health (NIH) to study the hepatitis ... is to develop a vaccine to protect people and ...

... trying to quit in the future could do ... according to research from The University of Nottingham. ... which exist naturally in our bodies (endocannabinoids), are ... treating conditions as diverse as obesity, diabetes, depression ...

... Herley Industries,Inc. (Nasdaq: HRLY ) expects to release ... March 12, 2008., A Conference Call has been ... 2008. Interested parties may join the conference by,dialing: (888) ... the conference call is scheduled to begin on March ...

... BERKELEY HEIGHTS, N.J., March 7 Genta,Incorporated (Nasdaq: ... entered into an,exclusive worldwide licensing agreement with Daiichi ... commercialization of tesetaxel,(formerly known as DJ-927). As a ... activity in its initial clinical trials, and,the drug ...

... will soon be possible for anyone over 60 to predict ... a simple web-based tool, developed by the Sydney-based Garvan Institute ... from the end of March at www.fractureriskcalculator.com , ... five factors including sex, age, weight, history of prior fracture, ...

... March 7 Novavax, Inc.,(Nasdaq: NVAX ) today ... full-year financial results in a press release to be ... 2008. The Company will hold an,investor conference call to ... Friday, March 14. The call will be hosted by ...

Other Medicine News:Health News:Human, animal vaccine development goal of hepatitis E virus research 2 Health News:Human, animal vaccine development goal of hepatitis E virus research 3 Health News:Curing addiction with cannabis medicines 2 Health News:Herley Industries, Inc. Second Quarter Earnings Release and Conference Call Notice 2 Health News:Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel 2 Health News:Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel 3 Health News:Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel 4 Health News:Launch of Web-based tool to predict risk of bone fracture 2 Health News:Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call 2

Human, animal vaccine development goal of hepatitis E virus research Curing addiction with cannabis medicines Herley Industries, Inc. Second Quarter Earnings Release and Conference Call Notice Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel Launch of Web-based tool to predict risk of bone fracture Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call

...

BD Vacutainer® Specialty Tubes - Trace Element - Glass...

Inquire...

BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....

Medicine Products:

MONOJECT Royal Blue Stopper (Powdered Additive)BD Vacutainer® Specialty Tubes - Trace Element - Glass MONOJECT Red Stopper (Non-Coated Tube)BD Vacutainer® Plus Plastic Serum Tubes - Plastic

Financial Results for Full Year 2007: NicOx Significantly Advances Clinica...(302 Minority interests in equity ...),Health